METADATA last updated: 2026-02-18 RT file_name: _context-commentary_various-fl-presentations_WIP.md category: various subcategory: fl-presentations words: 819 tokens: 1159 CONTENT ## Context The fl-presentations subcategory contains eight files: six slide decks and two one-page summary documents (the quad charts and a COVID-19 tests summary sheet). Together they document how FloodLAMP presented itself and its technology to different external audiences between mid-2021 and mid-2022. The presentations were prepared for specific occasions and audiences: - The **BARDA Market Research deck** (March 7, 2022) was prepared for a formal market research call with BARDA and is the single most comprehensive presentation in the subcategory. It covers the full FloodLAMP platform: assay technology (QuickColor LAMP and EasyPCR), real-world deployment data, the "point of need" operating model, digital tools, clinical evaluation results from Stanford, the open EUA regulatory strategy, and the case for variant resilience through multi-gene molecular testing. - The **New England BioLabs (NEB) seminar deck** (March 3, 2022) was prepared just four days earlier for an invited talk at NEB's facilities in Massachusetts. It shares substantial content with the BARDA deck but includes additional operational detail on specific pilot sites, a detailed preschool family screening case report, a New Year's Eve case report demonstrating early detection versus antigen and other rapid molecular tests, and more technical content on LAMP assay components, training workflows, and quality systems. - The **FDA Reagan-Udall Foundation deck** (April 21, 2022) was given during their monthly call, and presents a condensed version of FloodLAMP's vision and platform, emphasizing regulatory framing: the "open protocol" EUA concept, real-world surveillance data through the Omicron surge, and clinical evaluation results. - The **FTFC EMS Conference deck** (June 14, 2021) is the earliest presentation in the set, prepared for a talk at a fire/EMS leadership conference. It covers the core assay technology, clinical evaluation data, the school screening model, regulatory pathways and challenges, the open EUA comparison table, and the competitive landscape for K-12 screening providers. - The **Florida EMS Departments deck** (August 2022) targets EMS organizations and focuses on practical "point of need" deployment: FloodLAMP's advantages over CLIA-dependent and antigen-based alternatives, the turnkey solution including pooled collection, mobile app, training and quality system, and operational mechanics for an EMS employer screening program. - The **Quad Chart v1** (December 2021) and **Quad Chart v2** (January 2022) are structured one-page briefs summarizing objectives, deployments, performance metrics, milestones, risks, and funding structure for potential government or institutional funders. - The **COVID-19 Tests Summary** (May 2021) is a single-page overview of the two FloodLAMP tests, digital tools, clinical evaluation status, and regulatory posture. There is considerable content overlap across the presentations, particularly between the BARDA and NEB decks. This is typical for a small company adapting a core pitch for different audiences. Collectively the presentations show FloodLAMP's evolution from an early-stage pitch (FTFC conference in mid-2021) through increasingly data-rich and operationally detailed presentations (BARDA and NEB in early 2022) to the later Florida EMS outreach (mid-2022). Recurring themes include the "sweet spot" positioning of LAMP between antigen tests and centralized PCR, the open EUA strategy, real-world pilot data, and the vision for decentralized "point of need" molecular testing. Related materials include the proposals in various/fl-proposals, pilot program documentation in pilots/pilot-data and pilots/pilot-sites, the regulatory submissions in regulatory/fl-fda-submissions, the preschool whitepaper in various/fl-whitepapers, the open EUA concept explored in regulatory/open-euas, and the gLAMP consortium review paper in various/glamp. ## Commentary Communicating FloodLAMP's full picture, from the science to the operational model to the regulatory vision, was a persistent challenge. The company was attempting something unusual: not just a new test, but a complete decentralized screening platform with an open-source regulatory strategy, and that combination was difficult to convey in a slide deck. The presentations in this subcategory reflect that struggle, as well as the shifting strategic priorities as the company moved from pursuing FDA EUA authorization to building surveillance programs to seeking government funding and partnerships. The overlap between presentations illustrates both the core consistency of what FloodLAMP was building and the incremental adaptations made for each audience. The BARDA deck and NEB seminar, prepared days apart in early March 2022, represent the most mature articulation of the platform. By that point FloodLAMP had accumulated meaningful real-world data from multiple pilot sites and could present concrete screening statistics, nearly 30,000 people screened and hundreds of positives detected, alongside the clinical evaluation results from Stanford. The audience for these presentations ranged widely: BARDA officials evaluating market readiness, NEB scientists interested in LAMP chemistry, EMS leaders wanting practical deployment details, and FDA-adjacent stakeholders focused on regulatory innovation. The open EUA concept, which was central to FloodLAMP's strategy, required particularly careful framing because it challenged fundamental assumptions about how diagnostic tests are commercialized. The earlier FTFC EMS conference deck (June 2021) is notable for carrying a more overtly commercial tone, reflecting a period when FloodLAMP was still positioning for growth. By the time of the BARDA and NEB presentations in early 2022, the framing had changed. The later Florida EMS deck (August 2022) returned to a more practical, deployment-focused pitch.